JNJ

224.48

-1.31%↓

UNH

368.73

-0.08%↓

TMO

463.55

-1.22%↓

ISRG

450.2

-1.61%↓

ABT

87.99

-1.7%↓

JNJ

224.48

-1.31%↓

UNH

368.73

-0.08%↓

TMO

463.55

-1.22%↓

ISRG

450.2

-1.61%↓

ABT

87.99

-1.7%↓

JNJ

224.48

-1.31%↓

UNH

368.73

-0.08%↓

TMO

463.55

-1.22%↓

ISRG

450.2

-1.61%↓

ABT

87.99

-1.7%↓

JNJ

224.48

-1.31%↓

UNH

368.73

-0.08%↓

TMO

463.55

-1.22%↓

ISRG

450.2

-1.61%↓

ABT

87.99

-1.7%↓

JNJ

224.48

-1.31%↓

UNH

368.73

-0.08%↓

TMO

463.55

-1.22%↓

ISRG

450.2

-1.61%↓

ABT

87.99

-1.7%↓

Search

Simulations Plus Inc

Avatud

SektorTervishoid

14.83 4.66

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.73

Max

14.9

Põhinäitajad

By Trading Economics

Sissetulek

3.9M

4.5M

Müük

5.9M

24M

Aktsiakasum

0.35

Dividenditootlus

0.48

Kasumimarginaal

18.669

Töötajad

212

EBITDA

4.9M

7.2M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+7.31% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.48%

2.36%

Järgmine tulemuste avaldamine

13. juuli 2026

Turustatistika

By TradingEconomics

Turukapital

44M

295M

Eelmine avamishind

10.17

Eelmine sulgemishind

14.83

Uudiste sentiment

By Acuity

24%

76%

42 / 347 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. mai 2026, 23:47 UTC

Tulu

National Australia Bank Warns of Economic Shock as 1st Half Profit Falls -- Update

3. mai 2026, 22:35 UTC

Tulu

National Australia Bank Holds Dividend Despite 19% 1st Half Profit Drop

3. mai 2026, 23:39 UTC

Market Talk

Gold Edge Higher Amid Signs of Resilience -- Market Talk

3. mai 2026, 23:34 UTC

Market Talk

Oil Declines Amid Mild Risk-on Sentiment -- Market Talk

3. mai 2026, 23:32 UTC

Tulu

National Australia Bank Warns of Economic Shock as 1H Profit Falls -- Update

3. mai 2026, 23:30 UTC

Market Talk

Nickel Industries Result Shows Power of Higher Prices -- Market Talk

3. mai 2026, 23:20 UTC

Market Talk

RBA Likely to Hike Rates; Guidance and Board Split Key -- Market Talk

3. mai 2026, 23:16 UTC

Omandamised, ülevõtmised, äriostud

GameStop Is Offering to Buy eBay for $56 Billion, CEO Ryan Cohen Says -- WSJ

3. mai 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

GameStop Is Offering to Buy eBay For $56 Billion, CEO Ryan Cohen Says -- WSJ

3. mai 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

GameStop Has Roughly 5% Stake in eBay, Cohen Says -- WSJ

3. mai 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

GameStop Offering to Buy eBay for $125 a Share, or About $56 Billion, CEO Ryan Cohen Says -- WSJ

3. mai 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

GameStop Is Prepared to Run Proxy Fight If eBay Isn't Receptive to a Deal, Cohen Says -- WSJ

3. mai 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

GameStop Has Around $20 Billion in Debt Financing Committed From TD Bank, Cohen Says -- WSJ

3. mai 2026, 22:45 UTC

Market Talk

Global Equities Roundup: Market Talk

3. mai 2026, 22:45 UTC

Market Talk

Low-Cost Miners in Spotlight Amid High Energy Prices -- Market Talk

3. mai 2026, 22:20 UTC

Tulu

National Australia Bank Holds Dividend Despite 19% 1H Profit Drop

3. mai 2026, 22:08 UTC

Tulu

NAB's 1H Included Previously Announced A$1.35B Software Amortization Charge>NAB.AU

3. mai 2026, 22:05 UTC

Tulu

NAB 1H Net Interest Income A$9.16B Vs. A$8.445B>NAB.AU

3. mai 2026, 22:05 UTC

Tulu

NAB 1H Credit Impairment Charge A$706M Vs. A$348M>NAB.AU

3. mai 2026, 22:05 UTC

Tulu

NAB 1H Operating Expenses A$5.02B Vs. A$4.81B>NAB.AU

3. mai 2026, 22:04 UTC

Tulu

NAB 1H Net Interest Margin 1.81%>NAB.AU>NAB.AU

3. mai 2026, 22:03 UTC

Tulu

NAB 1H Cash Return on Equity Ex-Large Notable Items 11.6%>NAB.AU

3. mai 2026, 22:03 UTC

Tulu

NAB 1H Cash Return on Equity 8.5%>NAB.AU

3. mai 2026, 22:02 UTC

Tulu

NAB 1H CET1 Capital Ratio 11.65% Vs. 12.01%>NAB.AU

3. mai 2026, 22:02 UTC

Tulu

NAB 1H Cash Earnings A$2.64B>NAB.AU

3. mai 2026, 22:02 UTC

Tulu

NAB 1H Cash Earnings Ex-Notable Items A$3.59B Vs. A$3.58B>NAB.AU

3. mai 2026, 22:01 UTC

Tulu

National Australia Bank Keeps Dividend at A$0.85 >NAB.AU

3. mai 2026, 22:01 UTC

Tulu

National Australia Bank 1H Rev A$11.16B Vs. A$10.28B >NAB.AU

3. mai 2026, 22:01 UTC

Tulu

National Australia Bank 1H Net A$2.75B Vs. Net A$3.41B >NAB.AU

3. mai 2026, 15:06 UTC

Tulu

Berkshire's Greg Abel Marks His First Annual Meeting as CEO. We'd Give Him a B-Plus. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

7.31% tõus

12 kuu keskmine prognoos

Keskmine 16 USD  7.31%

Kõrge 16 USD

Madal 16 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

42 / 347 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat